Ozmosi | NH-130 Drug Profile
Contact Us
Drug Profile
Using advanced filters...
Advanced Search [+]

NH-130

Alternative Names: NH-130, NH 130, NH130
Clinical Status: Active
Latest Update: None
Latest Update Note: None

Product Description

Mechanisms of Action: 5-HT2A Inverse Agonist

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Company: Enhua Pharmaceutical
Company Location: Asia Pacific
Company Founding Year: None
Additional Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for NH-130

Countries in Clinic: China

Active Clinical Trial Count: 1

Recent & Upcoming Milestones

Highest Development Phases

Phase 1: Parkinson's Disease|Tic Disorders

Trial ID

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

Latest Trial Update Date

Data Updated

CTR20240362

 CTR20240362

P1

Completed

Parkinson's Disease|Tic Disorders

2025-02-05

2025-06-17

Patient Enrollment|Primary Completion Date|Study Completion Date|Treatments|Trial Status

Recent News Events

Date

Type

Title

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you've used PRYZM, we hope you're able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions